Bottom line
Prediabetes (HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL) is not yet an FDA-approved indication for any GLP-1. But the evidence that semaglutide and tirzepatide reverse prediabetes — reducing the hazard of progression to type 2 diabetes by 60–80% in trials — is among the strongest in the category.
For patients with prediabetes plus obesity (BMI ≥30) or overweight with a related condition (BMI ≥27), insurance coverage for weight management doses (Wegovy, Zepbound) is on-label. For patients with prediabetes alone, Ozempic or Mounjaro off-label is common but coverage-challenged.
Why prediabetes matters
Roughly 98 million U.S. adults meet prediabetes criteria — more than 1 in 3. Without intervention, 5–10% progress to type 2 diabetes per year; cumulative 10-year progression is about 70%. Intervention at the prediabetes stage is one of the highest-yield moments in medicine — reversing prediabetes typically normalizes cardiovascular risk, reduces cancer risk, and is substantially cheaper than treating established diabetes.
Standard-of-care interventions: 1. Intensive lifestyle modification (7% weight loss + 150 min/week exercise) — Diabetes Prevention Program data shows 58% reduction in progression over 3 years. 2. Metformin — 31% reduction in progression; recommended for high-risk patients (BMI ≥35, age <60, or prior gestational diabetes). 3. GLP-1s — off-label, but strongest evidence for weight loss and glycemic normalization.
The evidence for GLP-1s in prediabetes
Semaglutide (STEP-1 prediabetes subgroup). Among STEP-1 participants with prediabetes at baseline, 84% normalized their HbA1c on semaglutide 2.4 mg weekly versus 48% on placebo. In SUSTAIN trials with lower Ozempic doses, the effect was smaller but still substantial.
Tirzepatide (SURMOUNT-1 prediabetes subgroup). Similarly dramatic — about 95% of prediabetic SURMOUNT-1 participants normalized HbA1c on tirzepatide 15 mg over 72 weeks.
Long-term outcomes. The SURPASS-CVOT (tirzepatide in diabetes) and SELECT (semaglutide in obesity) trials both showed reductions in MACE events. No dedicated GLP-1 trial in prediabetes has measured progression-to-diabetes as the primary endpoint, but the subgroup analyses above are convincing.
Which GLP-1 for prediabetes?
Zepbound or Wegovy if the patient also meets BMI criteria for obesity — on-label, insurance cooperative.
Ozempic off-label for patients with prediabetes alone who don't meet weight-management BMI criteria. Coverage is uncertain; cash cost is high.
Metformin remains a reasonable first-line option, especially for cost-constrained patients, patients who don't meet obesity criteria, or patients who want to defer injectable therapy. Starting metformin and adding a GLP-1 if progression continues is a common stepped-care approach.
How fast does it work?
Fasting glucose typically drops within 2–4 weeks of starting a GLP-1, often before meaningful weight loss has occurred. HbA1c (which reflects 3-month average glycemia) follows over 3–6 months. Patients who will normalize their HbA1c usually do so by the 6-month mark.
If HbA1c doesn't improve despite weight loss, the differential includes inadequate dose, nonadherence, concurrent steroid or antipsychotic therapy, undiagnosed LADA (latent autoimmune diabetes in adults), or other rare causes.
When to stop
Patients often ask whether they can stop the GLP-1 after normalizing HbA1c. The honest answer: probably not without regaining weight and returning to prediabetes. The STEP-4 and SURMOUNT-4 trials both showed that stopping drug leads to regain; there's no published evidence that glucose normalization is durable off drug.
Sustained lifestyle modification (the 7%/150-min Diabetes Prevention Program standard) may allow some patients to step down or discontinue, but this is a high bar most people don't sustain.
Cost paths for prediabetes patients
Same as the weight-management cost stack, with one wrinkle: prediabetes alone is a very weak coverage argument. Most insurance plans require either a full type 2 diabetes diagnosis or qualifying obesity criteria.
For patients with prediabetes + obesity: the insurance guide walks through PA strategies.
For patients with prediabetes alone and no obesity: metformin first (cheap, well-covered), then cash GLP-1 through [program:trimrx] or [program:hims] if needed.
What your provider should monitor
Every 3 months initially: HbA1c, fasting glucose, weight, lipid panel. Every 6 months after stability: add liver function, renal function, and thyroid (if symptomatic).
If HbA1c drops below 5.5% and weight has stabilized, this is the point at which some prescribers attempt dose reduction — not discontinuation — to minimize long-term cumulative exposure while maintaining effect.